On this page
- Quick reference
- Dosage chart and four steps
- Supplies needed
- Vial and research context
- Protocol Overview
- Dosing Protocol
- Storage Instructions
- Oxytocin Measurement and Handling Notes
- How Oxytocin Works
- Published Human Oxytocin Dosing Research
- Why Route and Formulation Change the Meaning of a Dose
- Why Labor and Postpartum Oxytocin Dosing Is Separate
- Metabolic Research Findings and Their Limits
- Oxytocin Dosage Calculator Notes for a 5 mg Vial
- Subcutaneous Injection Technique Context
- Oxytocin Dosage Questions
- Important Note
- References
- Related research, protocols, and guides
Oxytocin Quick Reference (5 mg Vial)
- Vial contents
- 5 mg Oxytocin
- Final volume
- 3 mL
- Concentration
- 1.67 mg/mL
- One U-100 unit
- 16.67 mcg in 0.01 mL
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Oxytocin Peptide: Benefits, Uses, Side Effects, Dosage, and Research.
Oxytocin Dosage Chart
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 6 units (0.06 mL) |
| Weeks 3–4 | 200 mcg | 12 units (0.12 mL) |
| Weeks 5–6 | 300 mcg | 18 units (0.18 mL) |
| Weeks 7–8 | 400 mcg | 24 units (0.24 mL) |
| Weeks 9–12 | 500 mcg | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the standard 3.0 mL dilution for practical unit measurements on insulin syringes. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Oxytocin, 5 mg each):
- 8 weeks: approximately 3 vials required
- 12 weeks: approximately 6 vials required
- 16 weeks: approximately 9 vials required
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL — 1 bottle required (10 mL each)
- 12 weeks (6 vials): 18 mL — 2 bottles required (10 mL each)
- 16 weeks (9 vials): 27 mL — 3 bottles required (10 mL each)
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
- 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
- 16 weeks: 224 swabs — 3 boxes required (100 swabs each)
Oxytocin Vial and Research Context
- Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
- Typical daily range: 100–500 mcg once daily subcutaneous (gradual titration).
- Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F) or refrigerate at 2–8 °C (35.6–46.4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) under the exact product’s validated use-by and sterile-handling instructions.
Oxytocin is a nine-amino-acid peptide hormone and neurotransmitter with established roles in uterine contraction and milk ejection, along with ongoing research into social behavior, pain, appetite, and metabolism.[1][2] This oxytocin 5 mg dosage page keeps vial concentration and U-100 syringe calculations separate from route-specific human studies. A 5 mg lyophilized vial is a research product that requires preparation before measurement.[3] Intranasal, intravenous, obstetric, and subcutaneous findings are summarized as distinct evidence categories because their formulations and study designs are not interchangeable.
Protocol Overview
Concise summary of the once-daily regimen.
- Goal: Explore oxytocin’s effects on social bonding, stress reduction, metabolic function, and pain modulation[1][2].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 100–500 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen or refrigerated; reconstituted refrigerated according to formulation-specific use-by guidance; avoid repeated freeze–thaw cycles.
Dosing Protocol
Suggested daily titration approach based on published research protocols[4][5].
- Start: 100 mcg daily for 2 weeks; increase to 200 mcg for weeks 3–4.
- Titration: Increase by ~100 mcg every 2 weeks as tolerated (300 mcg weeks 5–6, 400 mcg weeks 7–8).
- Target: 500 mcg daily by weeks 9–12 (typical upper limit for research protocols).
- Frequency: Once per day (subcutaneous); rotate injection sites.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; oxytocin has rapid clearance, so effects are acute per dose.
Storage Instructions
Storage conditions depend on the exact formulation and product documentation.[15]
- Lyophilized: Follow the exact product’s labeling for frozen or refrigerated storage. Protect from light and moisture.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow the exact formulation’s validated use-by and sterile-handling instructions. Label the vial with the preparation date.
- Handling: Do not assume freezing a reconstituted solution extends its use-by interval. Follow formulation-specific stability and sterile-handling instructions.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Oxytocin Measurement and Handling Notes
Accurate documentation matters because an oxytocin mg vial, a dose in micrograms, a U-100 syringe marking, and a route-specific clinical formulation describe different things.
- Use a new sterile insulin syringe for each measurement and place used sharps in an approved puncture-resistant container.[12]
- Record the vial strength, measured final volume, concentration, syringe units, route, time, and site.
- Rotate subcutaneous sites when a repeated research design requires more than one administration; do not reuse the same point repeatedly.[13]
- Do not convert intranasal international units into injectable micrograms without formulation-specific potency and route data.
- Discard a prepared solution that is cloudy, discolored, or contains visible particles.
How Oxytocin Works
Oxytocin binds the oxytocin receptor, a G-protein-coupled receptor expressed in reproductive tissues and in several peripheral and central systems. Endogenous oxytocin is synthesized in the hypothalamus and released through the posterior pituitary. Its best-established physiological effects include uterine contraction during labor and milk ejection during lactation.[1][7]
Oxytocin also functions as a neuromodulator, which is why studies investigate social cognition, stress signaling, pain processing, food intake, and metabolic outcomes. Those findings depend on the route, formulation, population, exposure period, and outcome being measured. Preclinical prolonged subcutaneous research has examined food intake and body-mass effects, but animal findings are not human dosage evidence.[6] An observed effect after intranasal administration does not establish the same effect after subcutaneous injection, and an obstetric oxytocin infusion is not a peptide-vial protocol.
The controlled human subcutaneous experiment used a single local 4 mcg injection in 2 mL of prepared clinical solution. It reduced ratings of heat-pain intensity and unpleasantness on the injected arm, but it did not change mechanical pain, pressure pain, or heat-pain threshold.[8] That acute experiment provides route-specific mechanistic evidence; it does not replace the established calculation schedule displayed in this page’s primary chart.
Published Human Oxytocin Dosing Research
Human oxytocin administration studies use several delivery routes. Reading an oxytocin dosage requires the amount, route, formulation, frequency, and research purpose together.
| Evidence source | Route and study amount | Study design | Finding and limit |
|---|---|---|---|
| Albinni et al. | 4 mcg in 2 mL, one subcutaneous forearm injection | Randomized double-blind crossover experiment in 18 adults | Local heat-pain ratings decreased; this was not a repeated daily protocol.[8] |
| Plessow et al. | 24 IU intranasally, four times daily | Eight-week randomized placebo-controlled trial in 61 adults with obesity | Body weight did not differ from placebo; caloric intake at a test meal decreased as a secondary outcome.[4] |
| MacDonald et al. | Intranasal studies, commonly 18–40 IU per administration | Systematic safety review of controlled human research | Short-term exposure was generally well tolerated, but long-term safety and injectable schedules were not established.[9] |
| Hallschmid et al. | 24 IU, single intranasal administration | Randomized placebo-controlled crossover study in fasting men | Caloric intake decreased in the test-meal setting; the result does not establish a chronic injectable regimen.[10] |
| Brede et al. | 24 IU intranasally before an oral glucose tolerance test | Double-blind crossover study in men with type 2 diabetes | Acute glucose tolerance did not improve.[17] |
| Pedersen et al. | 0.2 IU/min intravenous infusion | Randomized double-blind crossover study in adults with obesity | The intravenous experiment did not support treating intranasal or subcutaneous amounts as equivalent.[18] |
Interpretation: These studies answer different questions. They provide useful human evidence, but no study row should be copied directly into a 5 mg vial syringe calculation without matching its exact route and formulation.
Why Route and Formulation Change the Meaning of a Dose
Intranasal oxytocin, intravenous oxytocin, an obstetric oxytocin injection, and a reconstituted lyophilized research vial differ in absorption, delivery device, concentration, and monitoring. International units in a nasal spray or finished injection are not automatically interchangeable with micrograms measured from a research vial.
- Subcutaneous research: The published pain experiment used a prepared 4 mcg/2 mL clinical solution and a single local injection.[8]
- Intranasal research: Trials often report IU delivered by a nasal device, with exposure and outcomes that depend on the formulation and administration technique.[4][9]
- Intravenous research: Infusion studies create systemic exposure under controlled clinical monitoring and cannot be converted into a home syringe row.[18]
- Obstetric use: Approved finished oxytocin injection is used for specific medical indications in monitored settings. It is not evidence for a general peptide dosage protocol.[14]
Why Labor and Postpartum Oxytocin Dosing Is Separate
Most clinical resources about oxytocin dosage describe induction of labor, stimulation or reinforcement of labor, or control of postpartum uterine bleeding. Those are specific medical indications managed with a finished oxytocin injection, an infusion protocol, and continuous assessment of uterine contraction pattern and fetal heart rate.[14]
FDA labeling discusses oxytocin use for medical induction, elective induction of labor when medically indicated, initiation of labor, labor augmentation, and postpartum hemorrhage. In those settings, oxytocin administration is titrated under continuous monitoring, with attention to the frequency of contractions, the contraction pattern, fetal heart rate, and the total dose. Safe administration in labor and delivery is therefore a hospital protocol, not a calculation example for a lyophilized vial.[14]
The prescribing information also describes contraindications for oxytocin and potentially serious adverse effects. Examples include total placenta previa, vasa previa, cord presentation or prolapse, active herpes genitalis, invasive cervical carcinoma, significant cephalopelvic disproportion, fetal distress when delivery is not imminent, and other conditions that contraindicate vaginal delivery. Potential adverse effects of excessive exposure include uterine rupture, antidiuretic effects, water intoxication, and complications of oxytocin overdose. This obstetric context prevents a common search-intent error: a labor induction dose, postpartum oxytocin dose, oxytocin infusion rate, or finished-drug dilution is not a calculation for a 5 mg research vial.
Search results may describe a 10 units in 500 mL or 1000 mL infusion and increase the mL infusion rate until the desired frequency of contraction is reached. Those numbers describe finished clinical products, medical indications, and monitored intravenous administration. They must not be transferred into this peptide-vial chart.
Metabolic Research Findings and Their Limits
Oxytocin has been investigated for food intake, body weight, body composition, glucose tolerance, and related metabolic outcomes. Early human studies reported reduced caloric intake after a single intranasal administration, while preclinical work described changes in food intake and visceral fat.[5][10] Reviews summarize possible mechanisms involving hypothalamic appetite signaling and energy expenditure, but they also emphasize that human evidence is limited.[11]
The larger eight-week randomized trial did not reduce body weight, body fat, visceral fat, liver fat, or resting energy expenditure compared with placebo.[4] A 2025 analysis from the same trial evaluated arginine-vasopressin dynamics because water balance is relevant to oxytocin safety and physiology.[16] Separate controlled studies did not show acute improvement in glucose tolerance in men with type 2 diabetes and did not establish equivalent effects for intravenous administration.[17][18]
These mixed findings are more informative than a benefit-only summary. They show why an oxytocin peptide dosage page should identify negative and neutral results, not only promising mechanisms.
Oxytocin Dosage Calculator Notes for a 5 mg Vial
The calculation starts with the vial mass and measured final volume. Five milligrams equals 5,000 mcg. Dividing 5,000 mcg by 3.0 mL gives approximately 1,666.67 mcg/mL. One U-100 syringe unit equals 0.01 mL, so one unit contains approximately 16.67 mcg.
- Micrograms to mL: desired mcg ÷ 1,666.67 mcg/mL = mL.
- Micrograms to U-100 units: desired mcg ÷ 16.67 mcg per unit = syringe units.
- Volume check: syringe units ÷ 100 = mL.
- Practical limit: arithmetic does not prove that a volume is accurately measurable or that an amount is appropriate for a different route or formulation.
The primary dosage and reconstitution chart above remains the controlling calculation schedule for this page. The formula explains its unit conversions without creating an additional schedule.
Subcutaneous Injection Technique Context
General subcutaneous technique references explain site cleaning, skin-fold selection, injection angle, rotation, and sharps disposal, but they do not validate oxytocin self-administration or establish an oxytocin dosage.[12][13]
- Prepare a clean work area and verify the labeled vial, concentration, and measured volume.
- Clean the vial stopper and selected site with separate alcohol swabs.
- Use a syringe whose graduations can resolve the intended volume; do not estimate between unreadable marks.
- Document the site and rotate locations when a repeated research design requires multiple administrations.
- Place used needles and syringes directly into an approved sharps container.
Oxytocin Dosage Questions
How much oxytocin is in one U-100 unit after adding 3 mL?
A 5 mg vial contains 5,000 mcg. At a 3.0 mL final volume, the concentration is approximately 1,666.67 mcg/mL. One U-100 unit is 0.01 mL, so it contains approximately 16.67 mcg.
Does the 5 mg vial determine the oxytocin dosage?
No. The vial strength determines the total peptide mass available. The final concentration depends on the measured diluent volume, while the displayed schedule determines the page’s calculation rows. A different vial strength changes concentration, units, yield, and supply math; it does not silently create a different biological schedule.
Is an oxytocin injection dosage for men different from the page’s chart?
This page does not create sex-specific schedules. Search phrases such as oxytocin injection for male dosage often combine route, population, and purpose without enough detail. A valid research interpretation requires the exact product, route, population, endpoint, and study design.
Can intranasal oxytocin study amounts be converted into this syringe chart?
Not directly. Intranasal studies use device-specific formulations and commonly report international units. Absorption and systemic exposure differ from subcutaneous or intravenous administration, so a simple IU-to-mcg conversion does not make the routes equivalent.
What did the eight-week obesity trial find?
Adults received 24 IU intranasally four times daily or placebo. The trial did not find a difference in body-weight change or major body-composition outcomes, although caloric intake at a test meal decreased as a secondary outcome.[4]
How should the prepared vial be stored?
Follow the exact product documentation for the unopened lyophilized vial. After preparation, refrigerate at 2–8 °C, protect from light, label the concentration and preparation date, and use a formulation-specific stability and sterile-handling plan.[3][15]
Important Note
This page summarizes oxytocin vial calculations and route-specific published research for educational purposes. It is not medical advice, does not replace monitored clinical care, and does not make intranasal, intravenous, obstetric, or subcutaneous formulations interchangeable.
References
- 1
Cleveland Clinic
: Oxytocin: What It Is, Function & Effects (overview of oxytocin hormone and its physiological roles) - 2
Wikipedia
: Oxytocin (comprehensive encyclopedia entry on oxytocin biochemistry, physiology, and research) - 3
Pure Lab Peptides
: Buy Oxytocin 5mg (product page for research oxytocin peptide) - 4
PubMed
: Intranasal Oxytocin for Obesity (8‑week trial using 96 IU per day in adults) - 5
Aging Journal
: Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass - 6
PLOS One
: Prolonged Subcutaneous Administration of Oxytocin in Male Rats (study on SC oxytocin effects) - 7
Science Direct
: The physiology and pharmacology of oxytocin in labor and in the puerperium - 8
PubMed
: Subcutaneous Oxytocin Injection Reduces Heat Pain: A Randomized‑Controlled Trial - 9
PubMed
: A review of safety, side‑effects and subjective reactions to intranasal oxytocin in human research - 10
PubMed
: The effects of oxytocin on eating behaviour and metabolism in humans - 11
PMC
: Oxytocin: A Potential Therapeutic for Obesity (review of oxytocin’s metabolic effects) - 12
Johns Hopkins Arthritis Center
: How to give a subcutaneous injection (step‑by‑step technique guide) - 13
PMC
: Pharmacologic Considerations in the Disposition of Antibodies and Antibody‑Drug Conjugates (subcutaneous drug injection review) - 15
FDA Accessdata
: Chemistry Review Document (oxytocin drug chemistry and stability information) - 14U.S. Food and Drug Administration: Oxytocin Injection prescribing information and approved obstetric-use context
- 16PubMed: Arginine-Vasopressin Dynamics During an Eight-Week Intranasal Oxytocin Trial
- 17PubMed: Oxytocin Does Not Acutely Improve Glucose Tolerance in Men With Type 2 Diabetes
- 18PubMed: Intravenous Oxytocin, Food Intake, and Postprandial Glucose in Adults With Obesity
Related research, protocols, and guides
Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.
Research overview
Other vial-strength protocols